GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Characterize Access to Specialty Care Received by American Indians/Alaska Natives
- Conditions
- Specialist Referral: OncologySpecialist Referral: NeurologySpecialist Referral: Ophthalmology
- Interventions
- Other: No Intervention
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT05624788
- Locations
- 🇺🇸
PPD Virtual - PPD - US, Wilmington, North Carolina, United States
🇺🇸Avera Research Institute, Sioux Falls, South Dakota, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Locally Advanced or Metastatic Solid TumorsNSCLCHNSCCMelanomaTNBCEsophageal CancerGastric CancerCervical CancerColorectal CancerUrothelial Carcinoma
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT05581004
- Locations
- 🇳🇱
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands
🇳🇱Universitair Medisch Centrum Groningen, Groningen, Netherlands
🇺🇸Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Advanced Solid TumorsMetastatic Solid Tumors
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 232
- Registration Number
- NCT05487235
- Locations
- 🇦🇷
Sanatorio Allende, Cordoba, Argentina
🇦🇷Fundacion CORI para la Investigacion y Prevencion del Cancer, La Rioja, Argentina
🇦🇷Centro Medico IPAM, Rosario, Argentina
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05462522
- Locations
- 🇫🇷
Centre Hospitalier Universitaire de Grenoble - Albert Michallon, La Tronche, France
🇫🇷Hopital Cochin, Paris, France
🇫🇷CHU de Bordeaux, Pessac, France
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
- Conditions
- Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT05306340
- Locations
- 🇯🇵
Nagoya University Hospital, Aichi, Japan
🇿🇦Medical Oncology Centre of Rosebank, Johannesburg, South Africa
🇪🇸Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología, La Coruña, LA Coruna, Spain
An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Other: No intervention
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05300724
- Locations
- 🇺🇸
Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, United States
🇩🇪Universitätsklinikum Bonn, Bonn, Germany
🇮🇱Rabin Medical Center, Petach Tikva, Israel
A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05243342
- Locations
- 🇳🇴
Oslo Universitetssykehus HF, Oslo, Norway
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Alfred Hospital, Melbourne, Victoria, Australia
Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
- Conditions
- Spinal Muscular Atrophy
- Interventions
- Device: SMA-DAT Application and ADAM Sensor
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 402
- Registration Number
- NCT05232929
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 218
- Registration Number
- NCT05224102
- Locations
- 🇺🇸
Scheie Eye Institute, Philadelphia, Pennsylvania, United States
🇺🇸Barnet Dulaney Perkins Eye Center, Phoenix, Arizona, United States
🇺🇸Win Retina, Arcadia, California, United States
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT05207670
- Locations
- 🇺🇸
Texas Oncology (Tyler) - USOR, Tyler, Texas, United States
🇺🇸Infirmary Cancer Care, Mobile, Alabama, United States
🇺🇸Alaska Oncology & Hematology, LLC, Anchorage, Alaska, United States